Details for Patent: 8,470,890

Title:	Method for enhancing the bioavailability of ospemifene
Abstract:	This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.
Inventor(s):	Markku; Anttila (Turku, FI)
Assignee:	Hormos Medical Ltd. (Turku, FI)
Filing Date:	Jul 06, 2012
Application Number:	13/543,166
Claims:	1. A method for enhancing the bioavailability of orally administered ospemifene or a pharmaceutically acceptable salt thereof, wherein said ospemifene or pharmaceutically acceptable salt thereof is administered orally to an individual in connection with the intake of foodstuff having nutritional value and causing secretion of bile acids to enhance bioavailability of the ospemifene or pharmaceutically acceptable salt thereof. 2. The method according to claim 1 wherein the ospemifene or pharmaceutically acceptable salt thereof is used for treatment of osteoporosis. 3. The method according to claim 1 wherein the ospemifene or pharmaceutically acceptable salt thereof is used for treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy. 4. The method according to claim 3 wherein the symptoms related to mucosal atrophy are urinary symptoms or vaginal symptoms. 5. The method according to claim 4 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day. 6. The method according to claim 5 wherein the dosage amount is 60 mg. 7. The method according to claim 1 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day. 8. The method according to claim 7 wherein the dosage amount is 60 mg. 9. A method for enhancing the bioavailability of orally administered ospemifene comprising orally administering the ospemifene to an individual in connection with the intake of a foodstuff having nutritional value and causing secretion of bile acids to enhance bioavailability of the ospemifene. 10. The method according to claim 9 wherein the ospemifene is used for treatment of osteoporosis. 11. The method according to claim 9 wherein the ospemifene is used for treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy. 12. The method according to claim 11 wherein the symptoms related to mucosal atrophy are urinary symptoms or vaginal symptoms. 13. The method according to claim 12 wherein the ospemifene is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day. 14. The method according to claim 13 wherein the dosage amount is 60 mg. 15. The method according to claim 9 wherein the ospemifene is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day. 16. The method according to claim 15 wherein the dosage amount is 60 mg. 17. A method of inhibiting urogenital atrophy comprising orally administering a therapeutically effective amount of ospemifene or a pharmaceutically acceptable salt thereof to a patient in need thereof in connection with the intake of a foodstuff having nutritional value and causing secretion of bile acids to enhance bioavailability of the ospemifene or pharmaceutically acceptable salt thereof. 18. The method according to claim 17 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day. 19. The method according to claim 18 wherein the dosage amount is 60 mg.